Laman UtamaGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
$7.21
Selepas Waktu Dagangan:(0.00%)0.00
$7.21
Tutup: 25 Apr, 8:00:00 PTG GMT-4 · USD · NASDAQ · Penafian
Tutup sebelumnya
$7.18
Julat hari
$7.15 - $7.33
Julat tahun
$5.79 - $9.96
Permodalan pasaran
5.99B USD
Bilangan Purata
984.18K
Dalam berita
GRF
0.78%
0.41%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(EUR) | Dis 2024info | Perubahan T/T |
---|---|---|
Hasil | 1.98B | 11.66% |
Perbelanjaan pengendalian | 353.12J | 20.32% |
Pendapatan bersih | 68.97J | 76.86% |
Margin untung bersih | 3.49 | 58.64% |
Pendapatan bagi setiap syer | — | — |
EBITDA | 495.68J | -11.49% |
Kadar cukai berkesan | 60.20% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(EUR) | Dis 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 1.00B | 55.40% |
Jumlah aset | 21.41B | 1.97% |
Jumlah liabiliti | 12.80B | -5.05% |
Jumlah ekuiti | 8.61B | — |
Syer tertunggak | 680.41J | — |
Harga kepada buku | 0.83 | — |
Pulangan pada aset | 5.08% | — |
Pulangan pada modal | 5.79% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(EUR) | Dis 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | 68.97J | 76.86% |
Tunai daripada operasi | 514.62J | 208.54% |
Tunai daripada pelaburan | -178.31J | -28.31% |
Tunai daripada pembiayaan | -27.16J | -185.08% |
Perubahan bersih dalam tunai | 334.84J | 658.87% |
Aliran tunai bebas | 162.44J | 123.56% |
Perihal
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Diasaskan
18 Nov 1940
Tapak web
Pekerja
23,833